key: cord-0996286-emw0fma2
authors: Syed, Mohamed Ahmed; A/Qotba, Hamda Abdulla; Al Nuaimi, Ahmed Sameer
title: Effectiveness of COVID-19 vaccines in Qatar
date: 2022-03-02
journal: J Infect
DOI: 10.1016/j.jinf.2022.02.034
sha: 86c70d02867ff392ff836fded3a152f114749ae6
doc_id: 996286
cord_uid: emw0fma2

nan

A recent study by Tré-Hardy et al (2021) published in this journal reported a marked and statistically significant antibody decrease between 3 and 6 months of receiving the second dose of mRNA-1273 vaccine 1 . We read it with great interest.

Initial randomised trials of severe acute respiratory coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines BNT162b2 and mRNA-1273 have each shown more than 90% efficacy in preventing corona virus disease 19 (COVID-19) 2,3 . More recent real world studies with longer follow up report waning immunity against infection over time 4 . We undertook a study to compare effectiveness of BNT162b2 Between month 2 to month 10 of follow up, effectiveness of BNT162b2 declined from 67.6 % to 12.5 %.

Similarly, effectiveness of mRNA-1273 decline from 84.5 % to 48.1 % (See Figure 1) . The decline was consistent between the two vaccine products until month 4. From month 4 onwards, the decline in BNT162b2 was significantly higher compared to mRNA-1273. At months 6-10, the difference between mRNA-1273 and BNT162b2 35.6 %.

The findings of the study demonstrate vaccine effectiveness of BNT162b2 and mRNA-1273 peaked at month 1. Following this, a significant decline was observed until the end of the follow up period for both vaccine products. Overall, mRNA-1273 was more effective in reducing SARS-CoV2 infections compared to BNT162b2, particularly after month 5. Similar findings have been reported in a sub-population of United State veterans 6 .

The difference in effectiveness could be attributed to higher humoral immunogenicity of mRNA-1273 compared with the BNT162b2 7 . Other reasons may be related to differences in mRNA content and time interval between the two doses between the two vaccine products. mRNA-1273 has higher mRNA content and longer interval between priming and boosting 8 .

While differences in vaccine effectiveness against risk of SARS-CoV2 between the two vaccine products are observed, the primary objective of mRNA vaccines is to protect against severe disease. Several studies have shown mRNA vaccine products offer high levels of protection against severe disease 9,10 .

Limitations of this study include the exclusion of data for individuals aged < 12 years old and the timing differences between the roll out of the two vaccine products.

In conclusion, there are differences in vaccine effectiveness between the two vaccine products against SARA-CoV2. However, both provide substantial protection against severe disease. 

Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Waning Immunity after the BNT162b2 Vaccine in Israel

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England

Comparative Effectiveness of Moderna